Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001140361-20-010147
Filing Date
2020-04-29
Accepted
2020-04-29 16:34:42
Documents
5
Effectiveness Date
2020-04-29

Document Format Files

Seq Description Document Type Size
1 DEFA 14A nc10011036x3_defa14a.htm DEFA14A 42252
2 nc10011036x3_noticecard01.jpg GRAPHIC 90303
3 nc10011036x3_noticecard02.jpg GRAPHIC 124651
4 nc10011036x3_noticecard03.jpg GRAPHIC 60149
5 nc10011036x3_noticecard04.jpg GRAPHIC 16884
  Complete submission text file 0001140361-20-010147.txt   442165
Mailing Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080 650.515.3185
CytomX Therapeutics, Inc. (Filer) CIK: 0001501989 (see all company filings)

EIN.: 273521219 | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-37587 | Film No.: 20830879
SIC: 2834 Pharmaceutical Preparations